vs
Side-by-side financial comparison of FUEL TECH, INC. (FTEK) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.2M, roughly 1.3× FUEL TECH, INC.). On growth, FUEL TECH, INC. posted the faster year-over-year revenue change (37.2% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-2.0M). Over the past eight quarters, FUEL TECH, INC.'s revenue compounded faster (20.9% CAGR vs -6.7%).
Rocket Fuel was an ad technology company based in Redwood City, California. It was founded in 2008 by alumni of Yahoo!.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
FTEK vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.2M | $9.1M |
| Net Profit | — | $-5.5M |
| Gross Margin | 44.6% | 49.4% |
| Operating Margin | -19.7% | -51.1% |
| Net Margin | — | -60.3% |
| Revenue YoY | 37.2% | -49.9% |
| Net Profit YoY | — | -184.8% |
| EPS (diluted) | $-0.05 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.2M | $9.1M | ||
| Q3 25 | $7.5M | $17.9M | ||
| Q2 25 | $5.6M | $15.7M | ||
| Q1 25 | $6.4M | $10.1M | ||
| Q4 24 | $5.3M | $18.2M | ||
| Q3 24 | $7.9M | $18.0M | ||
| Q2 24 | $7.0M | $13.5M | ||
| Q1 24 | $5.0M | — |
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $303.0K | $2.4M | ||
| Q2 25 | $-689.0K | $164.0K | ||
| Q1 25 | $-739.0K | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $80.0K | $3.2M | ||
| Q2 24 | $-421.0K | $-2.2M | ||
| Q1 24 | $281.0K | — |
| Q4 25 | 44.6% | 49.4% | ||
| Q3 25 | 48.9% | 53.4% | ||
| Q2 25 | 45.5% | 62.5% | ||
| Q1 25 | 46.4% | 19.1% | ||
| Q4 24 | 42.3% | 78.7% | ||
| Q3 24 | 43.4% | 53.4% | ||
| Q2 24 | 41.9% | 29.8% | ||
| Q1 24 | 40.9% | — |
| Q4 25 | -19.7% | -51.1% | ||
| Q3 25 | 0.1% | 11.9% | ||
| Q2 25 | -23.5% | 7.5% | ||
| Q1 25 | -14.9% | -41.0% | ||
| Q4 24 | -40.1% | 39.6% | ||
| Q3 24 | -2.3% | 22.2% | ||
| Q2 24 | -10.2% | -18.0% | ||
| Q1 24 | -34.1% | — |
| Q4 25 | — | -60.3% | ||
| Q3 25 | 4.0% | 13.2% | ||
| Q2 25 | -12.4% | 1.0% | ||
| Q1 25 | -11.6% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | 1.0% | 18.0% | ||
| Q2 24 | -6.0% | -16.4% | ||
| Q1 24 | 5.7% | — |
| Q4 25 | $-0.05 | $-0.06 | ||
| Q3 25 | $0.01 | $0.03 | ||
| Q2 25 | $-0.02 | $0.00 | ||
| Q1 25 | $-0.02 | $-0.05 | ||
| Q4 24 | $-0.06 | $0.10 | ||
| Q3 24 | $0.00 | $0.03 | ||
| Q2 24 | $-0.01 | $-0.03 | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.9M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $39.9M | $48.2M |
| Total Assets | $47.2M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.9M | $14.7M | ||
| Q3 25 | $25.9M | $13.6M | ||
| Q2 25 | $23.0M | $17.9M | ||
| Q1 25 | $21.8M | $19.5M | ||
| Q4 24 | $18.7M | $19.8M | ||
| Q3 24 | $20.4M | $27.4M | ||
| Q2 24 | $20.1M | $23.4M | ||
| Q1 24 | $23.3M | — |
| Q4 25 | $39.9M | $48.2M | ||
| Q3 25 | $41.0M | $52.9M | ||
| Q2 25 | $40.7M | $49.9M | ||
| Q1 25 | $41.4M | $45.2M | ||
| Q4 24 | $42.0M | $43.2M | ||
| Q3 24 | $43.9M | $32.4M | ||
| Q2 24 | $43.6M | $28.6M | ||
| Q1 24 | $44.0M | — |
| Q4 25 | $47.2M | $82.3M | ||
| Q3 25 | $47.9M | $82.3M | ||
| Q2 25 | $47.0M | $78.5M | ||
| Q1 25 | $46.7M | $73.9M | ||
| Q4 24 | $48.8M | $73.4M | ||
| Q3 24 | $50.1M | $61.6M | ||
| Q2 24 | $49.0M | $91.5M | ||
| Q1 24 | $49.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $2.0M |
| Free Cash FlowOCF − Capex | $-2.0M | $1.6M |
| FCF MarginFCF / Revenue | -27.7% | 17.8% |
| Capex IntensityCapex / Revenue | 6.1% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.6M | $2.0M | ||
| Q3 25 | $3.1M | $-3.7M | ||
| Q2 25 | $-21.0K | $-5.2M | ||
| Q1 25 | $1.5M | $-5.1M | ||
| Q4 24 | $-1.6M | $4.0M | ||
| Q3 24 | $879.0K | $4.1M | ||
| Q2 24 | $-1.6M | $-3.6M | ||
| Q1 24 | $-1.1M | — |
| Q4 25 | $-2.0M | $1.6M | ||
| Q3 25 | $3.0M | $-4.2M | ||
| Q2 25 | $-57.0K | $-5.7M | ||
| Q1 25 | $1.4M | $-5.4M | ||
| Q4 24 | $-1.7M | $3.6M | ||
| Q3 24 | $767.0K | $4.0M | ||
| Q2 24 | $-1.7M | $-3.8M | ||
| Q1 24 | $-1.2M | — |
| Q4 25 | -27.7% | 17.8% | ||
| Q3 25 | 39.6% | -23.7% | ||
| Q2 25 | -1.0% | -36.2% | ||
| Q1 25 | 22.6% | -53.0% | ||
| Q4 24 | -32.4% | 19.6% | ||
| Q3 24 | 9.8% | 22.4% | ||
| Q2 24 | -23.8% | -28.1% | ||
| Q1 24 | -24.0% | — |
| Q4 25 | 6.1% | 4.4% | ||
| Q3 25 | 1.7% | 2.8% | ||
| Q2 25 | 0.6% | 2.8% | ||
| Q1 25 | 1.0% | 3.0% | ||
| Q4 24 | 1.2% | 2.3% | ||
| Q3 24 | 1.4% | 0.5% | ||
| Q2 24 | 1.3% | 1.3% | ||
| Q1 24 | 2.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 10.22× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | 10.99× | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | -3.83× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FTEK
| Transferred At Point In Time | $5.3M | 73% |
| Other | $2.0M | 27% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
